A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Study Identifier
M06-884
CT.gov Identifier
NCT00491530
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dyslipidemia
    • Study Drug
  • ABT-335
  • rosuvastatin calcium
  • simvastatin
  • atorvastatin calcium
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Adult male and female subjects who voluntarily sign the informed consent. - Subject has successfully completed the treatment phase of the preceding open-label year 1 study.
    Exclusion Criteria:
    - Subject is using or will use investigational medications, except as approved by Abbott. - Subject has prematurely discontinued his/her combination therapy administered in the preceding open-label year 1 study.

    Protocol Summary

    The objective of the study is to assess the continued safety of the daily coadministration of

    ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.

    Study Locations

    Location
    Status
    Location
    Medical Information Specialist
    Abbott Park, Illinois, United States, 60064
    Status
    Not applicable